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News On: Cytosolic Hsp90α and its mitochondrial isoform Trap1 are differentially required in a breast cancer model by Vartholo-
maiou, et al. Oncotarget. 2017; 8(11):17428-42
Molecular chaperones are sophisticated machines 
that make possible the optimal activity of proteins by 
assisting their folding, assembly in multimeric complexes, 
conformational changes, subcellular trafficking and 
degradation. Most neoplastic cells overexpress molecular 
chaperones in order to cope with the high risk of incorrect 
protein folding caused by exposure to several stress 
stimuli, such as nutritional and pH fluctuations, inconstant 
oxygen availability, unbalances in redox equilibrium 
and genomic instability in a framework of relentless 
proliferation. Chaperone induction associates with 
cancer progression, resistance to chemotherapy and poor 
prognosis. As a corollary, chaperone-targeting drugs have 
raised great hopes as promising anti-tumor tools [1]. 
The HSP90 chaperone family is particularly 
relevant in neoplastic growth. The two cytosolic HSP90 
isoforms, HSP90α and HSP90β, interact with more than 
400 proteins, termed clients (https://www.picard.ch/
downloads/Hsp90interactors.pdf) and can tune the activity 
of several biochemical pathways whose deregulation is 
crucially involved in tumorigenesis. HSP90 chaperone 
activity facilitates conformational rearrangements in client 
proteins, thus avoiding their proteasomal degradation, 
and can be modulated by complex post-translational 
modifications and assembly of specific co-chaperones, 
allowing a high degree of plasticity to HSP90 functions 
[2]. 
Less is known about functions and clients of 
TRAP1, the mitochondrial chaperone of the HSP90 
family. Induction of TRAP1 correlates with progression, 
metastasis and disease recurrence in several neoplastic 
models [3]. TRAP1 shields tumor cells from oxidative 
stress and contributes to their metabolic rewiring by down-
regulating the activity of succinate dehydrogenase (SDH) 
and of cytochrome oxidase, the complex II and IV of the 
respiratory chain, respectively [4, 5]. 
Nonetheless, a detailed comprehension of the roles 
played by these chaperones in the tumorigenic process 
is lacking, which makes extremely difficult to reconcile 
under a unitary model the effects observed following their 
inhibition, and to design efficient therapeutic approaches. 
For instance, in several tumor types compounds targeting 
HSP90 can elicit growth arrest, but tumors start growing 
again after drug removal. Moreover, other HSPs, such 
as HSP70, can undergo compensatory induction, thus 
ablating inhibitor efficacy, and inhibition of any of the 
plethora of biological functions regulated by HSP90 can 
cause adverse effects in patients. In the case of TRAP1, 
its anti-oxidant and metabolic effects must be considered 
in the context of the multifaceted effects that ROS and 
bioenergetic adaptations could play on tumor growth. So, 
while in certain tumors high levels of TRAP1 are induced 
from very early stages of neoplastic progression in order 
to protect cells from oxidants [6], in other conditions 
oxidative stress might favor genetic instability and tumor 
aggressiveness. In these settings, the anti-oxidant effect of 
TRAP1 could hamper neoplastic progression, and indeed 
TRAP1 expression levels inversely correlate with tumor 
grade in specific tumor types [5]. 
Vartholomaiou, Madon-Simon et al. [7] add other 
elements to this scenario. By using a mouse model of 
breast cancer that exploits the oncogene polyoma virus 
middle T-antigen, they observe subtle and complex 
changes in tumorigenesis of animals where either HSP90α 
or TRAP1 have been knocked-out. None of these two 
chaperones influences tumor number or morphology, but 
in the absence of HSP90α tumor burden is decreased and 
lung metastases are less and smaller, whereas the lack of 
TRAP1 delays tumor onset without affecting burden or 
metastases. Therefore, HSP90α seems to be important in 
tumor growth, and TRAP1 in tumor onset. It is difficult to 
reconcile these differential effects caused by the absence of 
each chaperone to specific biological processes, as, at least 
in vitro, cells from these tumors lacking either HSP90α 
or TRAP1 are similarly less capable of proliferation, 
migration and invasion than their wild-type counterparts. 
Importantly, a meta-analysis carried out on a repository of 
gene expression data from breast cancer patients clearly 
indicates that mRNA expression levels of both HSP90α 
and TRAP1 correlate with tumor grade and, at least in the 
case of HSP90α, with time of survival. Accordingly, in 
the mouse model of Vartholomaiou et al. levels of the two 
chaperones, mainly of HSP90α, increase in tumors with 
respect to surrounding, non-transformed tissues.
These data highlight the need of additional 
information allowing to dissect how HSP90 and TRAP1 
contribute to tumor growth. We must exactly understand 
what are the biological processes required for breast 
tumorigenesis in which these chaperones play a crucial 
role. To this aim, it is mandatory to single out relevant 
clients whose functions are essential for tumor onset, 
primary growth, invasion and metastasis. It is possible that 
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a dynamic landscape of chaperone interactions changes 
according to signals funneled by oncogenic signalling 
pathways to HSP90 and TRAP1 via post-translational 
modifications (PTMs). PTMs affecting HSP90 are well 
established [2], even if their precise roles in neoplastic 
progression are far from clear. Notably, it is emerging that 
also TRAP1 interacts with kinases located in mitochondria, 
such as Src [5] and ERK1/2 [8], and that PTMs of TRAP1 
are relevant for tumorigenesis. In mitochondria of cells 
endowed with oncogenic induction of the Ras/ERK 
signalling pathway, ERK1/2 phosphorylates TRAP1 
and this enhances TRAP1-dependent inhibition of SDH, 
contributing to neoplastic growth via accumulation of the 
oncometabolite succinate [8]. 
Anti-cancer strategies aimed at targeting these 
molecular chaperones will greatly benefit from a detailed 
understanding of their mode of action and regulation in 
different tumor stages and types. Such information will 
make possible to design molecules that inhibit chaperone 
interactions with specific clients. These compounds could 
be associated with other anti-tumor drugs, with the aim of 
selectively targeting biological routines in which HSP90 
or TRAP1 play a crucial role. As a result, neoplastic 
cells would receive a much stronger and selective stress 
stimulus, hopefully resulting in a marked improvement in 
the therapeutic outcome with respect to single therapies.
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